MedTrace Logo

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

NCT04727541 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2022-05-23

No results posted yet for this study

Summary

The NEOBIL study aims to investigate the feasibility, safety and efficacy of neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer.

Conditions

Interventions

DRUG

Bintrafusp alfa

Neoadjuvant therapy with bintrafusp alfa

Sponsors & Collaborators

  • Merck Serono GmbH, Germany

    collaborator INDUSTRY

  • AIO-Studien-gGmbH

    lead OTHER

Principal Investigators

  • Oliver Waidmann, Prof.Dr. · Johann Wolfgang Goethe University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-08
Primary Completion
2021-10-04
Completion
2022-01-05

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04727541 on ClinicalTrials.gov